Seer shareholders back all company director nominees, reject activist slate and tax benefit preservation plan
SEER sits 43% above its 52-week low of $1.55 on elevated volume (2.6× avg).
Summary
Seer shareholders backed the incumbent board, defeating an activist challenge and rejecting the poison pill, as the company navigates a CEO buyout proposal.
Key Events · Corporate Governance and Compliance · SEER
-
All Company Nominees Elected
All seven company nominees, including CEO Omid Farokhzad, won election with favorable votes ranging from 19.1M to 34.2M. The activist candidates drew between 10.8M and 16.7M votes.
-
Activist Slate Defeated
The three Radoff-JEC Group nominees—Howard Berman, Joshua Horowitz, and Luis Rinaldini—were rejected, as shareholders withheld 26.9M, 32.8M, and 27.6M votes, respectively.
-
Tax Benefit Preservation Plan Not Ratified
The poison pill failed to secure ratification, receiving 19.9M votes in favor, 14.6M against, and 9.1M abstentions—short of the required majority. It will now expire according to its terms.
-
CEO Buyout Proposal Backdrop
The vote comes just weeks after CEO Farokhzad proposed taking Seer private at $2.45 per share plus two CVRs, an offer the board is evaluating through a special committee.
Analysis · SEER · Industrial Applications And Services
At the July 28 annual meeting, shareholders re-elected all seven company-backed directors, including CEO Omid Farokhzad, while turning down the three candidates put forward by the Radoff-JEC Group. The vote also failed to ratify the Tax Benefit Preservation Plan. This outcome cements the incumbent board's control in the midst of an activist proxy contest and a pending CEO-led take-private proposal at $2.45 per share. Stripping away the poison pill removes a takeover defense, which could leave the company more exposed to unsolicited bids, even as the board's victory strengthens its hand in evaluating the CEO's offer.
At the time of this filing, SEER was trading at $2.21 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $122.8M. The 52-week trading range was $1.55 to $2.41. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.